Cargando…
Exploring DrugCentral: from molecular structures to clinical effects
DrugCentral, accessible at https://drugcentral.org, is an open-access online drug information repository. It covers over 4950 drugs, incorporating structural, physicochemical, and pharmacological details to support drug discovery, development, and repositioning. With around 20,000 bioactivity data p...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692006/ https://www.ncbi.nlm.nih.gov/pubmed/37707619 http://dx.doi.org/10.1007/s10822-023-00529-x |
_version_ | 1785152848361684992 |
---|---|
author | Halip, Liliana Avram, Sorin Curpan, Ramona Borota, Ana Bora, Alina Bologa, Cristian Oprea, Tudor I. |
author_facet | Halip, Liliana Avram, Sorin Curpan, Ramona Borota, Ana Bora, Alina Bologa, Cristian Oprea, Tudor I. |
author_sort | Halip, Liliana |
collection | PubMed |
description | DrugCentral, accessible at https://drugcentral.org, is an open-access online drug information repository. It covers over 4950 drugs, incorporating structural, physicochemical, and pharmacological details to support drug discovery, development, and repositioning. With around 20,000 bioactivity data points, manual curation enhances information from several major digital sources. Approximately 724 mechanism-of-action (MoA) targets offer updated drug target insights. The platform captures clinical data: over 14,300 on- and off-label uses, 27,000 contraindications, and around 340,000 adverse drug events from pharmacovigilance reports. DrugCentral encompasses information from molecular structures to marketed formulations, providing a comprehensive pharmaceutical reference. Users can easily navigate basic drug information and key features, making DrugCentral a versatile, unique resource. Furthermore, we present a use-case example where we utilize experimentally determined data from DrugCentral to support drug repurposing. A minimum activity threshold t should be considered against novel targets to repurpose a drug. Analyzing 1156 bioactivities for human MoA targets suggests a general threshold of 1 µM: t = 6 when expressed as − log[Activity(M)]). This applies to 87% of the drugs. Moreover, t can be refined empirically based on water solubility (S): t = 3 − logS, for logS < − 3. Alongside the drug repurposing classification scheme, which considers intellectual property rights, market exclusivity protections, and market accessibility, DrugCentral provides valuable data to prioritize candidates for drug repurposing programs efficiently. |
format | Online Article Text |
id | pubmed-10692006 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-106920062023-12-03 Exploring DrugCentral: from molecular structures to clinical effects Halip, Liliana Avram, Sorin Curpan, Ramona Borota, Ana Bora, Alina Bologa, Cristian Oprea, Tudor I. J Comput Aided Mol Des Article DrugCentral, accessible at https://drugcentral.org, is an open-access online drug information repository. It covers over 4950 drugs, incorporating structural, physicochemical, and pharmacological details to support drug discovery, development, and repositioning. With around 20,000 bioactivity data points, manual curation enhances information from several major digital sources. Approximately 724 mechanism-of-action (MoA) targets offer updated drug target insights. The platform captures clinical data: over 14,300 on- and off-label uses, 27,000 contraindications, and around 340,000 adverse drug events from pharmacovigilance reports. DrugCentral encompasses information from molecular structures to marketed formulations, providing a comprehensive pharmaceutical reference. Users can easily navigate basic drug information and key features, making DrugCentral a versatile, unique resource. Furthermore, we present a use-case example where we utilize experimentally determined data from DrugCentral to support drug repurposing. A minimum activity threshold t should be considered against novel targets to repurpose a drug. Analyzing 1156 bioactivities for human MoA targets suggests a general threshold of 1 µM: t = 6 when expressed as − log[Activity(M)]). This applies to 87% of the drugs. Moreover, t can be refined empirically based on water solubility (S): t = 3 − logS, for logS < − 3. Alongside the drug repurposing classification scheme, which considers intellectual property rights, market exclusivity protections, and market accessibility, DrugCentral provides valuable data to prioritize candidates for drug repurposing programs efficiently. Springer International Publishing 2023-09-14 2023 /pmc/articles/PMC10692006/ /pubmed/37707619 http://dx.doi.org/10.1007/s10822-023-00529-x Text en © ©The Author(s) 2023, corrected publication 2023 https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Halip, Liliana Avram, Sorin Curpan, Ramona Borota, Ana Bora, Alina Bologa, Cristian Oprea, Tudor I. Exploring DrugCentral: from molecular structures to clinical effects |
title | Exploring DrugCentral: from molecular structures to clinical effects |
title_full | Exploring DrugCentral: from molecular structures to clinical effects |
title_fullStr | Exploring DrugCentral: from molecular structures to clinical effects |
title_full_unstemmed | Exploring DrugCentral: from molecular structures to clinical effects |
title_short | Exploring DrugCentral: from molecular structures to clinical effects |
title_sort | exploring drugcentral: from molecular structures to clinical effects |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692006/ https://www.ncbi.nlm.nih.gov/pubmed/37707619 http://dx.doi.org/10.1007/s10822-023-00529-x |
work_keys_str_mv | AT halipliliana exploringdrugcentralfrommolecularstructurestoclinicaleffects AT avramsorin exploringdrugcentralfrommolecularstructurestoclinicaleffects AT curpanramona exploringdrugcentralfrommolecularstructurestoclinicaleffects AT borotaana exploringdrugcentralfrommolecularstructurestoclinicaleffects AT boraalina exploringdrugcentralfrommolecularstructurestoclinicaleffects AT bologacristian exploringdrugcentralfrommolecularstructurestoclinicaleffects AT opreatudori exploringdrugcentralfrommolecularstructurestoclinicaleffects |